Isoptine

Verapamil, the active ingredient in Isoptine, is a calcium channel blocker presented as an injectable solution for intravenous use. It reduces myocardial contractility and vascular resistance, making it useful for controlling hypertension, relieving angina pectoris, and treating certain cardiac arrhythmias in adult patients.

GNH USA supplies Isoptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution with appropriate regulatory documentation. The company follows Good Distribution Practice, ensures product integrity during transit, and supports customers with technical and regulatory assistance.

Isoptine (verapamil) is used in cardiovascular therapy to control blood pressure, relieve chest pain, and manage abnormal heart rhythms. - Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. - Angina pectoris: alleviates chest pain by decreasing myocardial oxygen demand. - Supraventricular tachycardia: restores normal rhythm by slowing atrioventricular conduction. - Atrial fibrillation: helps control ventricular rate by reducing AV‑node conduction.

Verapamil may cause a range of adverse reactions, from mild to severe, that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after infusion. - Flushing: transient warmth and redness of the skin. - Dizziness: light‑headed sensation, especially when standing. - Peripheral edema: swelling of ankles or feet. - Nausea: mild gastrointestinal upset. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Severe hypotension: abrupt drop in blood pressure requiring intervention. - Bradycardia: markedly slow heart rate that may need pacing. - Heart block: impairment of electrical conduction, such as second‑degree AV block. - Acute myocardial infarction: rare worsening of heart ischemia. - Allergic reaction: anaphylaxis or severe skin rash. - Hepatotoxicity: abnormal liver enzymes indicating liver injury.

When using Isoptine, clinicians should observe several precautions to minimize risks and ensure optimal therapy. - Cardiovascular assessment: evaluate baseline blood pressure and heart rate before initiation. - Concomitant AV nodal blockers: avoid combining with beta‑blockers or digoxin without monitoring. - Renal impairment: adjust monitoring in patients with reduced renal function. - Electrolyte disturbances: correct hypokalemia or hypermagnesemia prior to therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Verapamil interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Beta‑blockers: additive bradycardia and AV block. - Digoxin: increased serum digoxin levels, risk of toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly raise verapamil concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, diuretics): enhanced hypotensive effect. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): increased risk of myopathy. - Anticonvulsants (e.g., carbamazepine): may reduce verapamil efficacy.